Halozyme Therapeutics Overview

Halozyme Therapeutics Operating Income

Operating Income for HALO.

Quarterly Operating Income

$184.52M

↑ 30.37% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$859.27M

↑ 43.82% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin